Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

US Department of Veterans Affairs (VA) logo

US Department of Veterans Affairs (VA)

Status

Completed

Conditions

HIV Infections

Treatments

Biological: Placebo
Biological: (PV) 23-valent pneumococcal polysaccharide vaccine

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT00706550
INDA-002-08S

Details and patient eligibility

About

The purpose of this study is to evaluate the best timing for administering pneumococcal vaccine (PV) to HIV-infected adults that have CD4 cell counts of more than 200 and are not yet receiving combination antiretroviral treatment (ART). Participants in this study will be assigned by chance to receive vaccination with PV prior to starting ART or after at least 6 months of ART. Antibody levels to components of the PV will be measured at 6 months and 12 months after vaccination. The results will tell us if patients that receive PV after 6 months of ART have better response to the vaccine than those that get vaccinated prior to treatment.

Enrollment

107 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HIV infected
  • CD4 count >200
  • no acute illness
  • no pneumococcal vaccination within 3 years
  • naive to treatment or if previously on treatment, no antiretroviral treatment for at least 6 months
  • willingness to start antiretroviral treatment as recommended by current guidelines

Exclusion criteria

  • prior pneumococcal vaccination within 3 years
  • prior AIDS diagnosis based on opportunistic disease
  • acute illness

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

107 participants in 2 patient groups

Immediate
Other group
Description:
Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment. PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine
Treatment:
Biological: (PV) 23-valent pneumococcal polysaccharide vaccine
Biological: Placebo
Delayed
Other group
Description:
Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment. PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine
Treatment:
Biological: (PV) 23-valent pneumococcal polysaccharide vaccine
Biological: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems